N/A
N=81
PatiEnt Neuropsychological outcomeS After laseR Ablation
Cognitive Change
Bottom Line
View on ClinicalTrials.gov: NCT05075850 ↗Enrolled (actual)
81
Serious AEs
0.0%
Results posted
Apr 2025
Primary outcome: Primary: Site-determined Cognitive Changes Per Domain — 49; 50.7; 32.9; 35.3 Score
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Neuroblate System (Device)
- Age
- Pediatric, Adult, Older Adult · 16+ yrs
- Sex
- All
- Sponsor
- Monteris Medical
- Primary completion
- Sep 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Site-determined Cognitive Changes Per Domain |
49; 50.7; 32.9; 35.3; 13.1; 14.6 | — |
| SECONDARY Change in Raw Test Scores From Standard Battery of Preferred Neuropsychological Tests |
25; 24; 30; 19; 29; 23 | — |
Summary
PatiEnt Neuropsychological outcomeS After laseR ablation
Eligibility Criteria
Inclusion Criteria
- Patient or legally authorized representative provides written authorization and/or consent.
- Patient is enrolled in the LAANTERN trial and had an epilepsy diagnosis without the presence of a malignant brain tumor.
- Patient is 16 years of age or older.
- Patient has completed a baseline comprehensive neuropsychological assessment with a neuropsychologist.
Exclusion Criteria
- Patient does not complete the index LITT procedure as specified in the LAANTERN registry.
Data sourced from ClinicalTrials.gov (NCT05075850). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.